One recent study demonstrated the ability of iloprost to stabilize adherens junctions and reduce endothelial-to-mesenchymal transition [49], while another suggested that the protective effects of iloprost could be attributed to downregulating CXCL10 release from endothelial cells and fibroblasts [50], together providing a mechanistic basis for the use of prostacyclin analogs in treating SSc patients with Raynaud’s phenomenon and digital ulcerations. This evidence concerns the gene CXCL10 and systemic sclerosis.